Feb 19 (Reuters) - Alzamend Neuro Inc ALZN.O:
ALZAMEND NEURO ANNOUNCES COMPLETION OF A NOVEL HEAD COIL BY TESLA FOR MEASURING BRAIN STRUCTURE LITHIUM LEVELS IN FIVE UPCOMING PHASE II CLINICAL TRIALS AT MASSACHUSETTS GENERAL HOSPITAL
Source text: ID:nBw3YrfS7a
Further company coverage: ALZN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.